Cormorant Asset Management’s Amicus Therapeutics FOLD Stock Holding History

Cormorant Asset Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-151,838	Closed	-$1.12M	–	83
2016 Q3	$1.12M	Hold	151,838	–	–	0.12%	70
2016 Q2	$829K	Buy	151,838 +1,838	+1%	+$12.9K	0.12%	69
2016 Q1	$1.27M	Hold	150,000	–	–	0.19%	67
2015 Q4	$1.46M	Hold	150,000	–	–	0.17%	65
2015 Q3	$2.1M	Sell	150,000 -50,000	-25%	-$784K	0.34%	59
2015 Q2	$2.83M	Buy	+200,000	New	+$2.4M	0.38%	53

Other funds holding FOLD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Cormorant Asset Management's FOLD Position: Q4 2016 in Review

Cormorant Asset Management sold out of Amicus Therapeutics (FOLD) in Q4 2016, closing a stake of 151,838 shares — an estimated $1.12M sold.

Cormorant Asset Management first reported a position in FOLD in Q2 2015 and held it in 6 quarters. The position peaked at $2.83M in Q2 2015. 135 funds tracked by Wall St. Rank hold FOLD as of Q4 2016.

Cormorant Asset Management reported no remaining Amicus Therapeutics position as of Q4 2016 after selling out during the quarter.
Cormorant Asset Management sold 151,838 Amicus Therapeutics shares in Q4 2016, an estimated $1.12M.
Cormorant Asset Management first reported a position in Amicus Therapeutics in Q2 2015 and held it in 6 quarters.
Cormorant Asset Management's Amicus Therapeutics position peaked at $2.83M in Q2 2015.
135 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2016.

Based on Cormorant Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.